Fibroblast-mediated extracellular matrix deposition

Fibroblast-mediated extracellular matrix deposition is not a single molecule or canonical therapeutic target, but rather a biological process by which fibroblasts, specialized mesenchymal cells, synthesize, secrete, and organize components of the extracellular matrix (ECM), including collagens, fibronectin, and proteoglycans[3][5]. This process is critical for maintaining tissue structure and enabling normal wound repair, but its dysregulation contributes to pathological conditions such as fibrosis and cancer by altering ECM composition, tissue stiffness, and immune cell infiltration[2][3][5]. Activated fibroblasts (often termed myofibroblasts) are particularly important in both physiological tissue repair and in promoting disease processes related to excessive or aberrant ECM remodeling[2][3]. There is no single druggable target with this name; rather, various pathways, cytokines, and cell surface receptors (such as TGF-β, IL-6, and integrins) regulate fibroblast-mediated ECM deposition[1][3][4]. Note: "Fibroblast-mediated extracellular matrix deposition" refers to a complex cellular process, not an individual protein, receptor, or gene. It is not a canonical target but rather a functional pathway/process relevant to many diseases, especially fibrosis and cancer[2][3][5].